Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM-CSF inhalation to improve host defense and pulmonary barrier restoration (GI-HOPE)
2014-002479-28Phase 2Completed
- Sponsor
- Justus Liebig University Giessen
- Start
- Apr 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sargramostim in acute respiratory distress syndrome (ARDS) and pneumonia (3 arms), sponsored by Justus Liebig University Giessen. Primary endpoint: GI-HOPE score change Day 4/5 vs Baseline. Started Apr 2015; status: completed.
02
Drugs
sargramostim
03
Conditions
acute respiratory distress syndrome (ARDS)pneumonia
Beyond the preview
Go deeper on 2014-002479-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002479-28.